<?xml version="1.0" encoding="UTF-8"?><TED_EXPORT xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns="http://publications.europa.eu/resource/schema/ted/R2.0.9/publication" xmlns:n2021="http://publications.europa.eu/resource/schema/ted/2021/nuts" xsi:schemaLocation="http://publications.europa.eu/resource/schema/ted/R2.0.9/publication TED_EXPORT.xsd" VERSION="R2.0.9.S05.E01" DOC_ID="214703-2023" EDITION="2023070"><TECHNICAL_SECTION><RECEPTION_ID>23-212597-001</RECEPTION_ID><DELETION_DATE>20230713</DELETION_DATE><FORM_LG_LIST>ES </FORM_LG_LIST><COMMENTS>From Convertor</COMMENTS></TECHNICAL_SECTION><LINKS_SECTION><XML_SCHEMA_DEFINITION_LINK xlink:type="simple" xlink:href="https://ted.europa.eu" xlink:title="TED WEBSITE"/><OFFICIAL_FORMS_LINK xlink:type="simple" xlink:href="https://ted.europa.eu"/><FORMS_LABELS_LINK xlink:type="simple" xlink:href="https://ted.europa.eu"/><ORIGINAL_CPV_LINK xlink:type="simple" xlink:href="https://ted.europa.eu"/><ORIGINAL_NUTS_LINK xlink:type="simple" xlink:href="https://ted.europa.eu"/></LINKS_SECTION><CODED_DATA_SECTION><REF_OJS><COLL_OJ>S</COLL_OJ><NO_OJ>70</NO_OJ><DATE_PUB>20230407</DATE_PUB></REF_OJS><NOTICE_DATA><NO_DOC_OJS>2023/S 070-214703</NO_DOC_OJS><URI_LIST><URI_DOC LG="ES">https://ted.europa.eu/udl?uri=TED:NOTICE:214703-2023:TEXT:ES:HTML</URI_DOC></URI_LIST><LG_ORIG>ES</LG_ORIG><ISO_COUNTRY VALUE="ES"/><IA_URL_GENERAL>http://www.madrid.org/contratospublicos</IA_URL_GENERAL><ORIGINAL_CPV CODE="33652100">Antineoplastic agents</ORIGINAL_CPV><n2021:PERFORMANCE_NUTS CODE="ES30">Comunidad de Madrid</n2021:PERFORMANCE_NUTS><n2021:CA_CE_NUTS CODE="ES30">Comunidad de Madrid</n2021:CA_CE_NUTS><n2021:TENDERER_NUTS CODE="ES300">Madrid</n2021:TENDERER_NUTS><VALUES><VALUE TYPE="PROCUREMENT_TOTAL" CURRENCY="EUR">796469.92</VALUE></VALUES></NOTICE_DATA><CODIF_DATA><DS_DATE_DISPATCH>20230404</DS_DATE_DISPATCH><AA_AUTHORITY_TYPE CODE="3">Regional or local authority</AA_AUTHORITY_TYPE><TD_DOCUMENT_TYPE CODE="7">Contract award notice</TD_DOCUMENT_TYPE><NC_CONTRACT_NATURE CODE="2">Supplies</NC_CONTRACT_NATURE><PR_PROC CODE="T">Negotiated without a prior call for competition</PR_PROC><RP_REGULATION CODE="5">European Union, with participation by GPA countries</RP_REGULATION><TY_TYPE_BID CODE="9">Not applicable</TY_TYPE_BID><AC_AWARD_CRIT CODE="1">Lowest price</AC_AWARD_CRIT><MA_MAIN_ACTIVITIES CODE="H">Health</MA_MAIN_ACTIVITIES><HEADING>01B03</HEADING><INITIATOR>01</INITIATOR></CODIF_DATA></CODED_DATA_SECTION><TRANSLATION_SECTION><ML_TITLES><ML_TI_DOC LG="BG"><TI_CY>Иcпaния</TI_CY><TI_TOWN>Alcalá de Henares</TI_TOWN><TI_TEXT><P>Антинеопластични средства</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="CS"><TI_CY>Španělsko</TI_CY><TI_TOWN>Alcalá de Henares</TI_TOWN><TI_TEXT><P>Antineoplastika</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="DA"><TI_CY>Spanien</TI_CY><TI_TOWN>Alcalá de Henares</TI_TOWN><TI_TEXT><P>Cytostatika</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="DE"><TI_CY>Spanien</TI_CY><TI_TOWN>Alcalá de Henares</TI_TOWN><TI_TEXT><P>Antineoplastische Mittel</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="EL"><TI_CY>Ισπανία</TI_CY><TI_TOWN>Alcalá de Henares</TI_TOWN><TI_TEXT><P>Αντινεοπλασματικά φάρμακα</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="EN"><TI_CY>Spain</TI_CY><TI_TOWN>Alcalá de Henares</TI_TOWN><TI_TEXT><P>Antineoplastic agents</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="ES"><TI_CY>España</TI_CY><TI_TOWN>Alcalá de Henares</TI_TOWN><TI_TEXT><P>Agentes antineoplásicos</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="ET"><TI_CY>Hispaania</TI_CY><TI_TOWN>Alcalá de Henares</TI_TOWN><TI_TEXT><P>Antineoplastilised ained</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="FI"><TI_CY>Espanja</TI_CY><TI_TOWN>Alcalá de Henares</TI_TOWN><TI_TEXT><P>Solunsalpaajat ja sytostaatit</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="FR"><TI_CY>Espagne</TI_CY><TI_TOWN>Alcalá de Henares</TI_TOWN><TI_TEXT><P>Antinéoplasiques</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="GA"><TI_CY>Spáinn, an</TI_CY><TI_TOWN>Alcalá de Henares</TI_TOWN><TI_TEXT><P>Antineoplastic agents</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="HR"><TI_CY>Španjolska</TI_CY><TI_TOWN>Alcalá de Henares</TI_TOWN><TI_TEXT><P>Antineoplastični lijekovi</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="HU"><TI_CY>Spanyolország</TI_CY><TI_TOWN>Alcalá de Henares</TI_TOWN><TI_TEXT><P>Daganatellenes szerek</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="IT"><TI_CY>Spagna</TI_CY><TI_TOWN>Alcalá de Henares</TI_TOWN><TI_TEXT><P>Agenti antineoplastici</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="LT"><TI_CY>Ispanija</TI_CY><TI_TOWN>Alcalá de Henares</TI_TOWN><TI_TEXT><P>Antinavikiniai vaistai</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="LV"><TI_CY>Spānija</TI_CY><TI_TOWN>Alcalá de Henares</TI_TOWN><TI_TEXT><P>Antineoplastiskie līdzekļi</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="MT"><TI_CY>Spanja</TI_CY><TI_TOWN>Alcalá de Henares</TI_TOWN><TI_TEXT><P>Aġenti ta' l-antineoplastika</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="NL"><TI_CY>Spanje</TI_CY><TI_TOWN>Alcalá de Henares</TI_TOWN><TI_TEXT><P>Antineoplastische middelen</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="PL"><TI_CY>Hiszpania</TI_CY><TI_TOWN>Alcalá de Henares</TI_TOWN><TI_TEXT><P>Środki przeciwnowotworowe</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="PT"><TI_CY>Espanha</TI_CY><TI_TOWN>Alcalá de Henares</TI_TOWN><TI_TEXT><P>Antineoplásicos</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="RO"><TI_CY>Spania</TI_CY><TI_TOWN>Alcalá de Henares</TI_TOWN><TI_TEXT><P>Antineoplazice</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="SK"><TI_CY>Španielsko</TI_CY><TI_TOWN>Alcalá de Henares</TI_TOWN><TI_TEXT><P>Antineoplastické činidlá</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="SL"><TI_CY>Španija</TI_CY><TI_TOWN>Alcalá de Henares</TI_TOWN><TI_TEXT><P>Zdravila z delovanjem na novotvorbe</P></TI_TEXT></ML_TI_DOC><ML_TI_DOC LG="SV"><TI_CY>Spanien</TI_CY><TI_TOWN>Alcalá de Henares</TI_TOWN><TI_TEXT><P>Cytostatika/cytotoxiska medel</P></TI_TEXT></ML_TI_DOC></ML_TITLES><ML_AA_NAMES><AA_NAME LG="ES">Hospital Universitario Príncipe de Asturias</AA_NAME></ML_AA_NAMES></TRANSLATION_SECTION><FORM_SECTION><F03_2014 CATEGORY="ORIGINAL" FORM="F03" LG="ES"><LEGAL_BASIS VALUE="32014L0024"/><CONTRACTING_BODY><ADDRESS_CONTRACTING_BODY><OFFICIALNAME>Hospital Universitario Príncipe de Asturias</OFFICIALNAME><NATIONALID>Q2877035B</NATIONALID><ADDRESS>Carretera Alcalá-Meco, s/n</ADDRESS><TOWN>Alcalá de Henares</TOWN><POSTAL_CODE>28805</POSTAL_CODE><COUNTRY VALUE="ES"/><CONTACT_POINT>Hospital Universitario Príncipe de Asturias</CONTACT_POINT><PHONE>+34 918878100/2285</PHONE><E_MAIL>contratacion.hupa@salud.madrid.org</E_MAIL><FAX>+34 918828738</FAX><n2021:NUTS CODE="ES30"/><URL_GENERAL>http://www.madrid.org/contratospublicos</URL_GENERAL></ADDRESS_CONTRACTING_BODY><CA_TYPE VALUE="REGIONAL_AUTHORITY"/><CA_ACTIVITY VALUE="HEALTH"/></CONTRACTING_BODY><OBJECT_CONTRACT><TITLE><P>PNSP HUPA 179/22 Tagrisso comp 80 mg </P></TITLE><REFERENCE_NUMBER>PNSP HUPA 179/22</REFERENCE_NUMBER><CPV_MAIN><CPV_CODE CODE="33652100"/></CPV_MAIN><TYPE_CONTRACT CTYPE="SUPPLIES"/><SHORT_DESCR><P>Suministro de medicamentos Tagrisso comp 80 mg para el Hospital Universitario Príncipe de Asturias</P></SHORT_DESCR><VAL_TOTAL CURRENCY="EUR">796469.92</VAL_TOTAL><NO_LOT_DIVISION/><OBJECT_DESCR ITEM="1"><n2021:NUTS CODE="ES30"/><SHORT_DESCR><P>Suministro de medicamentos Tagrisso comp 80 mg para el Hospital Universitario Príncipe de Asturias</P></SHORT_DESCR><AC><AC_PRICE/></AC><NO_OPTIONS/><NO_EU_PROGR_RELATED/></OBJECT_DESCR></OBJECT_CONTRACT><PROCEDURE><PT_AWARD_CONTRACT_WITHOUT_CALL><D_ACCORDANCE_ARTICLE><D_PROTECT_RIGHTS/></D_ACCORDANCE_ARTICLE><D_JUSTIFICATION><P>Se considera sistema idóneo el procedimiento negociado sin publicidad por exclusividad, en base a lo preceptuado en los artículos 163.a, 131.2, 166.1 y 168 a) 2º de la LCSP. La elección del procedimiento negociado sin publicidad por exclusividad se realiza de conformidad con el artículo 116.4 de Ley de Contratos del Sector Público 9/17, de 8 de noviembre (LCSP).</P></D_JUSTIFICATION></PT_AWARD_CONTRACT_WITHOUT_CALL><CONTRACT_COVERED_GPA/></PROCEDURE><AWARD_CONTRACT ITEM="1"><TITLE><P>Medicamentos Tagrisso comp 80 mg</P></TITLE><AWARDED_CONTRACT><DATE_CONCLUSION_CONTRACT>2023-03-24</DATE_CONCLUSION_CONTRACT><TENDERS><NB_TENDERS_RECEIVED>1</NB_TENDERS_RECEIVED></TENDERS><CONTRACTORS><NO_AWARDED_TO_GROUP/><CONTRACTOR><ADDRESS_CONTRACTOR><OFFICIALNAME>ASTRAZENECA FARMACÉUTICA SPAIN, S.A.</OFFICIALNAME><NATIONALID>A36002129</NATIONALID><ADDRESS>Calle Serrano Galvache, 56</ADDRESS><TOWN>Madrid</TOWN><POSTAL_CODE>28033</POSTAL_CODE><COUNTRY VALUE="ES"/><PHONE>+34 606723503</PHONE><n2021:NUTS CODE="ES300"/></ADDRESS_CONTRACTOR><NO_SME/></CONTRACTOR></CONTRACTORS><VALUES><VAL_ESTIMATED_TOTAL CURRENCY="EUR">2230115.77</VAL_ESTIMATED_TOTAL><VAL_TOTAL CURRENCY="EUR">796469.92</VAL_TOTAL></VALUES></AWARDED_CONTRACT></AWARD_CONTRACT><COMPLEMENTARY_INFO><ADDRESS_REVIEW_BODY><OFFICIALNAME>Tribunal Administrativo de Contratación Pública de la Comunidad de Madrid</OFFICIALNAME><ADDRESS>Plaza Chamberí, 8, 5ª planta</ADDRESS><TOWN>Madrid</TOWN><POSTAL_CODE>28010</POSTAL_CODE><COUNTRY VALUE="ES"/><PHONE>+34 917206346</PHONE><E_MAIL>tribunal.contratacion@madrid.org</E_MAIL><FAX>+34 917206347</FAX></ADDRESS_REVIEW_BODY><ADDRESS_REVIEW_INFO><OFFICIALNAME>Servicio de Suministros del Hospital Universitario Príncipe de Asturias</OFFICIALNAME><ADDRESS>Carretera Alcalá-Meco, s/n</ADDRESS><TOWN>Alcalá de Henares</TOWN><POSTAL_CODE>28805</POSTAL_CODE><COUNTRY VALUE="ES"/><PHONE>+34 918878100-2285</PHONE><E_MAIL>contratacion.hupa@salud.madrid.org</E_MAIL><FAX>+34 918828738</FAX></ADDRESS_REVIEW_INFO><DATE_DISPATCH_NOTICE>2023-04-04</DATE_DISPATCH_NOTICE></COMPLEMENTARY_INFO></F03_2014></FORM_SECTION></TED_EXPORT>